Paradromics completes first-in-human recording with Connexus BCI — high-bandwidth implant validated in human cortex
Summary
Paradromics announced via LinkedIn that the company completed its first-in-human recording with the Connexus Brain-Computer Interface — a milestone widely noted in Neurotech Notables #46 (January 2026). The first acute Connexus implantation was performed at the University of Michigan by Dr. Willsey, validating the high-bandwidth recording architecture in human cortex for the first time. Paradromics CEO Matt Angle has been outspoken about the information transfer rate advantage of Connexus over competing systems, including publishing a detailed blog post titled "Neuralink device limitation." Paradromics subsequently received FDA IDE approval (November 2025) to begin the Connect-One clinical trial at MGH under PI Leigh Hochberg.
Why it matters
First-in-human Connexus recording at the University of Michigan is the clinical milestone that transitions Paradromics from pre-clinical to human-validated status — the most important threshold in BCI device development. Combined with the near-simultaneous FDA IDE approval for Connect-One at MGH, Paradromics enters 2026 with both first human data and an active US clinical trial, positioning them as a credible competitor to Neuralink and Synchron.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial